CSPC Pharmaceutical recombinant herpes zoster vaccine Sys6052 gets FDA clinical trial approval

CSPC Pharmaceutical Group Limited said its recombinant herpes zoster vaccine (Sys6052) obtained FDA clinical trial approval in the US.